Business Wire

AWS and Formula 1 Announce New Racing Performance Stats for 2020 Season

Share

Today, Amazon Web Services, Inc. (AWS), an Amazon.com company (NASDAQ: AMZN), and Formula 1 (F1) (NASDAQ: FWONA, FWONK) are introducing six new, real-time racing statistics that will roll out through the 2020 season, beginning with the launch of “Car Performance Scores” at the season opening Grand Prix in Spielberg, Austria July 3-5. “Car Performance Scores” isolate an individual car’s performance and allows race fans to compare its performance to that of different vehicles head-to-head. The new set of statistics to be released this season will use a range of AWS services, including machine learning, to give fans the ability to compare their favorite drivers and cars and better predict race outcomes. Learn more at: https://aws.amazon.com/f1/.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200623005380/en/

F1 Insights Powered by AWS - Car Performance Scores. Courtesy of F1.

F1 Insights Powered by AWS - Car Performance Scores. Courtesy of F1.

With 300 sensors on each F1 race car generating more than 1.1M data points per second transmitted from the cars to the pit, Formula 1 is a truly data-driven sport where much of the thrill comes from extracting exciting details on performance statistics. F1 relies on the breadth and depth of AWS services to stream, process, and analyze that flood of data in real-time, and then present it in a meaningful way for F1 global TV viewers. The new “Car Performance Scores” insight will display as an on-screen graphic that provides fans with a complete breakdown of a car’s total performance using four core metrics: Low-Speed Cornering, High-Speed Cornering, Straight Line, and Car Handling. The new graphic will illustrate how those metrics compare from one car to another, enabling race fans to gauge a given car’s relative performance in those different areas and see where each team and driver is leading the pack or losing crucial time to their rivals.

F1 and AWS previously announced six F1 Insights, including Exit Speed, Predicted Pit Stop Strategy, Pit Window, Battle Forecast, Pit Strategy Battle, and Tyre Performance and will roll out the following six additional “F1 Insights powered by AWS” stats as on-screen graphics from July through December of this season, offering fans more visibility into the split-second decision-making and action on the track, as well as behind the pit wall where the team strategists operate:

  • Car Performance Scores: Isolates an individual car’s performance and allows race fans to compare its performance to that of different vehicles head-to-head (debuts July 3-5 at the FORMULA 1 ROLEX GROSSER PREIS VON ÖSTERREICH GRAND PRIX 2020).
  • Ultimate Driver Speed Comparison: Allows race fans to see how their favorite drivers compare to other drivers in history, dating back to 1983, to help determine the fastest driver of all time (debuts August 7-9 at the EMIRATES FORMULA 1 70th ANNIVERSARY GRAND PRIX 2020).
  • High-Speed/Low-Speed Corner Performance: Allows fans to see how well drivers tackle the fastest bends on the track travelling at more than 175 kph/109 mph and slow cornering (below 125 kph/78 mph) compared to other vehicles, which is critical to lap time (debuts August 28-30 at the FORMULA 1 ROLEX BELGIAN GRAND PRIX).
  • Driver Skills Rating: Breaks down and scores driver skills, based on the most important factors for overall performance, to help identify the best “total driver” on the track. By calculating varying subsets of qualifying round performance, starts, race pace, tire management, and overtaking/defending styles, this insight will provide an overall driver ranking (debuts the second half of the season).
  • Car/Team Development & Overall Season Performance: As the season unfolds,this will plot a team’s cumulative performance from race to race to uncover the development rates of each team (debuts the second half of the season).
  • Qualifying and Race Pace Predictions: Gather data from practice and qualifying laps to predict which team is poised for success ahead of each race session. These predictions will create heightened intrigue and excitement for the Saturday qualifying session and Sunday race (debuts the second half of the season).

To create these new insights, Formula 1 will use 70 years of historical race data stored in Amazon Simple Storage Service (Amazon S3), combined with live data that is streamed from sensors on F1 race cars and the trackside to the cloud through Amazon Kinesis, a service for real-time data collection, processing, and analysis. F1 engineers and scientists will use this data to leverage machine learning (ML) models with Amazon SageMaker, AWS’s service for building, training, and deploying ML models. F1 is able to analyze race performance metrics in real-time by deploying those ML models on AWS Lambda, which runs code without the need to provision or manage servers. All of the insights will be integrated into the international broadcast feed of F1 races around the globe, including its digital platform F1.tv, helping fans to understand the split-second decisions and race strategies made by drivers or team strategists that can dramatically affect a race outcome.

“Over the past two years, Formula 1 has embraced AWS’s services to perform intense and dynamic data analysis. The F1 Insights we’re delivering together are bringing fans closer to the track than ever before, and unlocking previously untold stories and insights from behind the pit wall,” said Rob Smedley, Chief Engineer of Formula 1. “We’re excited to be expanding this successful relationship to bring even more insights to life, allowing fans to go deeper into the many ways that drivers and racing teams work together to affect success.”

“Formula 1 racing mixes physics and human performance, yielding powerful, but complex data that AWS is helping them to harness. Our existing relationship with F1 has already produced statistics that have brought fans into the race paddocks, and our study of race car aerodynamics is influencing vehicle designs for the 2022 season,” said Mike Clayville, Vice President, Worldwide Commercial Sales at AWS. “This year, we’re thrilled to extend the power of F1 data in the cloud and unlock new insights that help fans understand more of F1’s rich complexity.”

To learn more about the first 2020 F1 Insight, Car Performance Scores, please click here. For more information about AWS and its involvement with Formula 1, please visit: https://aws.amazon.com/f1/. For additional news on how AWS is helping Formula 1 develop the next-generation race car, visit: https://aws.amazon.com/f1/news/.

About Amazon Web Services

For 14 years, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud platform. AWS offers over 175 fully featured services for compute, storage, databases, networking, analytics, robotics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, virtual and augmented reality (VR and AR), media, and application development, deployment, and management from 76 Availability Zones (AZs) within 24 geographic regions, with announced plans for nine more Availability Zones and three more AWS Regions in Indonesia, Japan, and Spain. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visit aws.amazon.com.

About Amazon

Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.

About Formula 1®

Formula 1® racing began in 1950 and is the world’s most prestigious motor racing competition, as well as the world’s most popular annual sporting series. The 2020 FIA Formula One World Championship™ runs from March to November and spans 22 races in 22 countries across five continents. Formula One World Championship Limited is part of Formula 1® and holds the exclusive commercial rights to the FIA Formula One World Championship™. Formula 1® is a subsidiary of Liberty Media Corporation (NASDAQ: LSXMA, LSXMB, LSXMK, BATRA, BATRK, FWONA, FWONK) attributed to the Formula One Group tracking stock. The F1 logo, F1 FORMULA 1 logo, FORMULA 1, F1, FIA FORMULA ONE WORLD CHAMPIONSHIP, GRAND PRIX, PADDOCK CLUB and related marks are trademarks of Formula One Licensing BV, a Formula 1 company. All rights reserved.

Contact information

Amazon.com, Inc.
Media Hotline
Amazon-pr@amazon.com
www.amazon.com/pr

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ESMO 2020: Cabometyx ® (cabozantinib) in Combination With Opdivo ® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 18:30:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 12:55:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 12:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 09:30:00 CESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 08:00:00 CESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 07:00:00 CESTPress release

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a